Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...
The FDA has approved the biologics license application (BLA) for the subcutaneous (SC) administration of pembrolizumab ...
AstraZeneca announced that the Phase III TULIP-SC trial of SAPHNELO (anifrolumab) for treatment of people with systemic lupus ...
In September 2025, Merck received FDA approval for KEYTRUDA QLEX, a subcutaneous version of its flagship cancer therapy, ...
In September 2025, the U.S. Food and Drug Administration (FDA) approved several new cancer therapies and supportive care ...
Pharmaceutical Technology on MSN
Halozyme eyes microparticles in $900m Elektrofi acquisition
Halozyme will purchase fellow subcutaneous drug delivery specialist Elektrofi for $750m upfront, along with with three ...
The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the ...
A new analysis from the PALOMA-2 study presented today shows that subcutaneous administration of amivantamab every four weeks (Q4W), in combination with daily oral lazertinib, yields a high objective ...
An interim analysis of the TULIP-SC trial found that weekly subcutaneous delivery of Saphnelo significantly reduced disease ...
Developed by Johnson & Johnson, guselkumab is the first approved fully-human, dual-acting IL-23p19 subunit inhibitor that blocks IL-23 and binds to CD64, a receptor on cells that produce IL-23.4,12,13 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback